Who is sponsoring NCT06105658?

NCT06105658 is sponsored by Anhui Provincial Hospital.

What drugs are being tested in NCT06105658?

Interventions in NCT06105658: Unrelated umbilical cord blood, Venetoclax, Decetabine, Azacitidine.

What condition does NCT06105658 study?

NCT06105658 studies Acute Myelocytic Leukemia.

Is NCT06105658 still recruiting?

NCT06105658 is currently status unknown. Last updated 27 October 2023.

Last reviewed 2023-10-27 · How we verify

NCT06105658

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate the Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Acute Myelocytic Leukemia

Status unknown Phase 2 Last updated 27 October 2023

What this trial tests

Phase 2 trial testing Unrelated umbilical cord blood in Acute Myelocytic Leukemia in 20 participants. Status unknown.

Timeline

1 October 2023

Primary endpoint
1 February 2024

1 February 2026

Quick facts

Lead sponsor	Anhui Provincial Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 October 2023
Primary completion	1 February 2024
Estimated completion	1 February 2026
Sites	1 location across China

Drugs / interventions tested

Unrelated umbilical cord blood — full drug profile →
Venetoclax (venetoclax) — full drug profile →
Decetabine — full drug profile →
Azacitidine (azacitidine) — full drug profile →

Conditions studied

Acute Myelocytic Leukemia — all drugs for Acute Myelocytic Leukemia →

Sponsor

Anhui Provincial Hospital

Who can join

Adults 14 to 80, any sex, with Acute Myelocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete response (CR) rate
Time frame: 28±7days
CR rate is defined as the percentage of patients who met the following conditions: Myelogram: naïve cells less than 5% (at least 200 nucleated cells); Hemogram: absolute neutrophil count \> 1.0×10\^9/L, platelet count \> 100×10\^9/L; Clinical diagnosis: no symptoms and signs caused by leukemia infiltration, and patients do not rely on blood transfusion.
Hematopoietic recovery time
Time frame: 28±7days
The time of absolute neutrophil count\>0.5×10\^9/L and platelet count \>30×10\^9/L for 3 consecutive days.

Sponsor's own description

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of AML patients by observing the factors related to the efficacy and adverse reactions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Myelocytic Leukemia

Currently open trials in the same condition.

NCT06764589 — Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood · active not recruiting

Other Anhui Provincial Hospital trials

Trials by the same sponsor.

NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06105658 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
Last refreshed: 27 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06105658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing